Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States.
Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States; Research Services-Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, United States.
J Nutr. 2023 Dec;153(12):3418-3429. doi: 10.1016/j.tjnut.2023.09.018. Epub 2023 Sep 27.
Nonalcoholic fatty liver disease (NAFLD) prevalence is rapidly growing, and fatty liver has been found in a quarter of the US population. Increased liver lipids, particularly those derived from the pathway of de novo lipogenesis (DNL), have been identified as a hallmark feature in individuals with high liver fat. This has led to much activity in basic science and drug development in this area. No studies to date have investigated the contribution of DNL across a spectrum of disease, although it is clear that inhibition of DNL has been shown to reduce liver fat.
The purpose of this study was to determine whether liver lipid synthesis increases across the continuum of liver injury.
Individuals (n = 49) consumed deuterated water for 10 d before their scheduled bariatric surgeries to label DNL; blood and liver tissue samples were obtained on the day of the surgery. Liver lipid concentrations were quantitated, and levels of protein and gene expression assessed.
Increased liver DNL, measured isotopically, was significantly associated with liver fatty acid synthase protein content (R = 0.470, P = 0.003), total steatosis assessed by histology (R = 0.526, P = 0.0008), and the fraction of DNL fatty acids in plasma very low-density lipoprotein-triacylglycerol (R = 0.747, P < 0.001). Regression analysis revealed a parabolic relationship between fractional liver DNL (percent) and NAFLD activity score (R = 0.538, P = 0.0004).
These data demonstrate that higher DNL is associated with early to mid stages of liver disease, and this pathway may be an effective target for the treatment of NAFLD and nonalcoholic steatohepatitis. This study was registered at clinicaltrials.gov as NCT03683589.
非酒精性脂肪性肝病 (NAFLD) 的患病率正在迅速上升,四分之一的美国人口患有脂肪肝。在肝脏脂肪含量高的人群中,已经发现肝内脂质增加,特别是来自从头合成 (DNL) 途径的脂质增加,这是一个标志性特征。这导致该领域的基础科学和药物开发活动非常活跃。迄今为止,尚无研究调查 DNL 在疾病谱中的贡献,尽管抑制 DNL 已被证明可减少肝脂肪。
本研究旨在确定肝脂质合成是否在肝损伤连续体中增加。
49 名个体在接受减肥手术前 10 天饮用氘水以标记 DNL;手术当天获得血液和肝组织样本。定量肝脂质浓度,并评估蛋白和基因表达水平。
同位素测量的肝 DNL 增加与肝脂肪酸合酶蛋白含量显著相关(R = 0.470,P = 0.003),组织学评估的总脂肪变性(R = 0.526,P = 0.0008),以及 DNL 脂肪酸在血浆极低密度脂蛋白-三酰甘油中的分数(R = 0.747,P < 0.001)。回归分析显示,肝 DNL 分数(%)与 NAFLD 活动评分之间呈抛物线关系(R = 0.538,P = 0.0004)。
这些数据表明,较高的 DNL 与肝病的早期至中期阶段相关,该途径可能是治疗 NAFLD 和非酒精性脂肪性肝炎的有效靶点。本研究在 clinicaltrials.gov 上注册为 NCT03683589。